We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+20.34%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.16B
AUM Growth
+$284M
Cap. Flow
+$60M
Cap. Flow %
1.44%
Top 10 Hldgs %
34.47%
Holding
129
New
1
Increased
41
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25M
3
BAX icon
Baxter International
BAX
+$21.2M
4
BPMC
Blueprint Medicines
BPMC
+$16.9M
5
IRON icon
Disc Medicine
IRON
+$16.9M

Top Sells

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$35.1M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$16.4M
3
ARVN icon
Arvinas
ARVN
+$12.5M
4
GOSS icon
Gossamer Bio
GOSS
+$9.97M
5
OHPAU
Orion Acquisition Corp. Unit
OHPAU
+$9.87M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
2 Consumer Staples 0.83%
3 Industrials 0.36%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.81B
$56.5M 1.36%
436,000
+6,000
+1% +$695K
DXCM icon
27
DexCom
DXCM
$33.1B
$55.5M 1.34%
490,500
– –
ASND icon
28
Ascendis Pharma A/S
ASND
$16.8B
$52M 1.25%
425,500
– –
SGEN
29
DELISTED
Seagen Inc. Common Stock
SGEN
$51.4M 1.24%
400,200
+128,200
+47% +$16.5M
RYTM icon
30
Rhythm Pharmaceuticals
RYTM
$7.95B
$51.3M 1.23%
1,760,865
– –
EW icon
31
Edwards Lifesciences
EW
$53B
$48.2M 1.16%
645,900
+14,900
+2% +$1.15M
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.21B
$46.4M 1.12%
1,175,672
+19,711
+2% +$718K
AMLX icon
33
Amylyx Pharmaceuticals
AMLX
$2.53B
$45.4M 1.09%
1,229,637
+825,900
+205% +$29.3M
PRTA icon
34
Prothena Corp
PRTA
$468M
$45.4M 1.09%
753,462
+75,000
+11% +$4.39M
EXAS
35
DELISTED
Exact Sciences
EXAS
$43.9M 1.06%
887,500
+308,900
+53% +$12.6M
WST icon
36
West Pharmaceutical
WST
$24.8B
$43.7M 1.05%
185,500
+5,000
+3% +$1.18M
NVRO
37
DELISTED
NEVRO CORP.
NVRO
$42.7M 1.03%
1,077,900
+290,900
+37% +$12.1M
PHR icon
38
Phreesia
PHR
$769M
$42.1M 1.01%
1,302,500
– –
PCRX icon
39
Pacira BioSciences
PCRX
$974M
$39.9M 0.96%
1,032,600
+15,100
+1% +$735K
OLK
40
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$36.7M 0.88%
1,445,000
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$36.5M 0.88%
805,024
-61,752
-7% -$4M
MIRM icon
42
Mirum Pharmaceuticals
MIRM
$6.02B
$35M 0.84%
1,795,733
– –
FRPT icon
43
Freshpet
FRPT
$3.26B
$34.7M 0.83%
657,000
-43,000
-6% -$2.56M
ABCM
44
DELISTED
Abcam PLC
ABCM
$33.9M 0.82%
2,180,000
+147,500
+7% +$2.3M
ZLAB icon
45
Zai Lab
ZLAB
$2.65B
$32.5M 0.78%
1,059,700
-132,700
-11% -$4.19M
KYMR icon
46
Kymera Therapeutics
KYMR
$9.03B
$30.6M 0.74%
1,227,779
+181,036
+17% +$4.83M
IRTC icon
47
iRhythm Holdings
IRTC
$4.1B
$29M 0.7%
309,450
+16,200
+6% +$1.76M
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$13.3B
$27.4M 0.66%
264,500
– –
XLV icon
49
State Street Health Care Select Sector SPDR ETF
XLV
$44B
$27.2M 0.65%
200,000
– –
CMPX icon
50
Compass Therapeutics
CMPX
$400M
$26.8M 0.65%
5,333,188
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rock Springs Capital Management held 129 positions worth $4.16B, up 7.3% from $3.87B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management's Q4 2022 filing shows 1 new, 41 increased, 24 reduced and 9 closed positions. Its largest new stake was Disc Medicine: 339,497 shares worth $6.75M. The largest sale was Covetrus, Inc. Common Stock, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2022 buy was Disc Medicine: 339,497 shares worth $6.75M.
  • Rock Springs Capital Management added most to Amylyx Pharmaceuticals in Q4 2022, an estimated $29.3M increase.
  • Rock Springs Capital Management's biggest Q4 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $16.4M.
  • Rock Springs Capital Management fully exited Covetrus, Inc. Common Stock in Q4 2022, selling an estimated $35.1M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.16B portfolio in Q4 2022.
  • Rock Springs Capital Management opened 1 new position and closed 9 in Q4 2022.
  • Rock Springs Capital Management's portfolio value rose 7.3% quarter-over-quarter to $4.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.